Genentech Articles
Geron names Stephen Kelsey CFO and Hassan Movahhed as VP
30 April 2009
Stock Commentary - Europe - week to April 27, 2009
30 April 2009
Biogen's 1st-qtr profit jumps 54% to $244M
20 April 2009
Roche announces details of Genentech management shake-up
16 April 2009
Stock Commentary - Europe - week to April 13, 2009
16 April 2009
AZ eyeing up small European firms
15 April 2009
SCLC drug market wil more than double to $648M in 2017
14 April 2009
Stock Commentary - New York week to March 30, 2009
2 April 2009
NexGen founder's patent improves chemo
30 March 2009
Roche completes tender offer for Genentech
30 March 2009
OSI submits Tarceva in Europe and USA
30 March 2009
Mylan group sued over for first-to-file ANDAs
27 March 2009
Stock Commentary - Europe - week to Mar 16, 2009
23 March 2009
Rituxan fails Ph III lupus nephritis trial
16 March 2009
Stock Commentary - Europe - week to Mar 9, 2009
16 March 2009
Stock Commentary - New York week to Mar 9, 2009
16 March 2009
Genentech accepts Roche $95/share bid
16 March 2009
Roche upped bid still gets Genentech's "no"
16 March 2009
Roche found guilty of UK Code violation again
9 March 2009
Roche raises further $14B in bonds to buy Genentech
2 March 2009
USPTO upholds Genentech's Cabilly patent
2 March 2009
Genentech advises shareholders to reject Roche's $86.50 per share bid; growing hostility
2 March 2009
Profit soars for OSI on income tax credit
2 March 2009
Roche sells $16B of bonds to finance renewed Genentech bid
23 February 2009
Roche goes hostile in bid for Genentech, offering $86.50 a share
16 February 2009
Stock Commentary - Europe - week to Feb 9, 2009
16 February 2009
Stock Commentary - Europe - week to Feb 2, 2009
9 February 2009
OSI shares jump 11.4% on Tarceva/Avastin benefit in NSCLC
9 February 2009
Roche goes hostile, lowers Genentech bid
9 February 2009
Genentech names Jennifer Doudna as VP of discovery research
26 January 2009
Roche to make new offer for Genentech?
19 January 2009
Stock Commentary - New York week to Jan 5, 2009
12 January 2009
Rituxan slows joint damage in early RA
12 January 2009
MorphoSys names Arndt Schottellius as CDO
15 December 2008
Stock Commentary - New York week to Dec 8, 2008
15 December 2008
Rituxan plus chemo boosts PFS in Ph III CLL trials
15 December 2008
Genentech licenses more ImmunoGen TAP tech
15 December 2008
Avastin increases PFS in advanced breast cancer
1 December 2008
Another PML case for Genentech's Raptiva
24 November 2008
Tarceva extends PFS in advanced NSCLC
17 November 2008
Biogen and Genentech to co-develop cancer MAb
17 November 2008
Avastin sBLA submitted for glioblastoma
17 November 2008
Kyowa Kirin hopes to become a biotech major
10 November 2008
CLARIFICATION: Genzyme's Campath Ph II trial results
27 October 2008
UPDATE: Roche
27 October 2008
Roche reports 9-month sales figures
27 October 2008
Ph III Avastin gets interim DMC go-ahead
27 October 2008
Genentech refuses to comment on Roche merger
20 October 2008
Genzyme's Campath does well in Ph II CLL trial
20 October 2008
Potential new use for rituximab in CLL
13 October 2008
Roche/Genentech license GlycArt's GA101
13 October 2008
Credit crisis makes Roche bid uncertain
13 October 2008
Tarceva plus Avastin miss Ph III endpoint
13 October 2008
Speculation that GSK may acquire Genmab
13 October 2008
PML doctor warnings issued for Raptiva
13 October 2008
Genentech appoints Morgan Sheng as VP, neuroscience
22 September 2008
EPO revokes Genentech/Biogen patent
22 September 2008
Genentech/Biogen Idec's Rituxan linked to death of RA patient due to PML
22 September 2008
Roche to close Californian plant
15 September 2008
Genentech's $379M retention plan
1 September 2008
Stock Commentary - Europe - week to Aug 11, 2008
18 August 2008
Stock Commentary - New York week to Aug 11, 2008
18 August 2008
Genentech says Roche offer undervalues the firm
18 August 2008
Rx drug prices "double" US political impact
18 August 2008
Stock Commentary - Europe - week to July 28m 2008
4 August 2008
Genentech convenes c'tee to assess Roche offer
4 August 2008
Biogen's 2nd-qtr 2008 revenue up 28%
4 August 2008
Stock Commentary - New York week to July 21, 2008
28 July 2008
Stock Commentary - Europe - week to July 21, 2008
28 July 2008
Roche buys RNAi firm Mirus for $125M
28 July 2008
BioInvent swings back into profit in 2nd qtr
28 July 2008
Avastin plus Sutent trial ended on anemia fears
21 July 2008
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
